Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;31(4):196-204.
doi: 10.1089/apc.2017.0002.

"Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation

Sarah K Calabrese  1   2   3 , Manya Magnus  4 , Kenneth H Mayer  5   6 , Douglas S Krakower  5   6 , Adam I Eldahan  2   7 , Lauren A Gaston Hawkins  2   8 , Kristen Underhill  3   9   10 , Nathan B Hansen  3   11 , Trace S Kershaw  2   3 , Joseph R Betancourt  12 , John F Dovidio  2   3   13
Affiliations

"Support Your Client at the Space That They're in": HIV Pre-Exposure Prophylaxis (PrEP) Prescribers' Perspectives on PrEP-Related Risk Compensation

Sarah K Calabrese et al. AIDS Patient Care STDS. 2017 Apr.

Abstract

Despite the demonstrated effectiveness of HIV pre-exposure prophylaxis (PrEP) and evidence that most PrEP users do not engage in risk compensation (i.e., increased risk behavior due to a perceived decrease in HIV susceptibility), some healthcare providers report patient risk compensation to be a deterrent to prescribing PrEP. Overcoming this barrier is essential to supporting PrEP access and uptake among people at risk for HIV. To inform such efforts, this qualitative study explored PrEP-related risk compensation attitudes among providers with firsthand experience prescribing PrEP. US-based PrEP providers (n = 18), most of whom were HIV specialists, were recruited through direct outreach and referral from colleagues and other participants. Individual 90-min semistructured interviews were conducted by phone or in person from September 2014 through February 2015, transcribed, and thematically analyzed. Three attitudinal themes emerged: (1) providers' role is to support patients in making informed decisions, (2) risk behavior while taking PrEP does not fully offset PrEP's protective benefit (i.e., PrEP confers net protection, even with added behavioral risk), and (3) PrEP-related risk compensation is unduly stigmatized within and beyond the healthcare community. Participants were critical of other healthcare providers' negative judgment of patients and reluctance to prescribe PrEP due to anticipated risk compensation. Several providers also acknowledged an evolution in their thinking from initial ambivalence toward greater acceptance of PrEP and PrEP-related behavior change. PrEP providers' insights about risk compensation may help to address unsubstantiated concerns about PrEP-related risk compensation and challenge the acceptability of withholding PrEP on these grounds.

Keywords: HIV; behavioral disinhibition; condom attitudes; healthcare providers; pre-exposure prophylaxis; risk compensation.

PubMed Disclaimer

Conflict of interest statement

SKC, DSK, and KHM have received compensation for their efforts in developing and/or delivering medical education related to PrEP. DSK and KHM have conducted research with unrestricted project support from Gilead Sciences, and KHM has conducted research with unrestricted project support from Merck and ViiV Healthcare.

References

    1. U.S. Centers for Disease Control and Prevention. HIV surveillance report: Diagnosis of HIV infection in the United States and dependent areas, 2015. 2016. Available at: www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-re... (Last accessed February9, 2017)
    1. Mayer KH, Ramjee G. The current status of the use of oral medication to prevent HIV transmission. Curr Opin HIV AIDS 2015;10:226–232 - PMC - PubMed
    1. U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States: A clinical practice guideline. 2014. Available at: www.cdc.gov/hiv/pdf/prepguidelines2014.pdf (Last accessed February9, 2017)
    1. White House Office of National AIDS Policy. National HIV/AIDS strategy for the United States: Updated to 2020. 2015. Available at: www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf (Last accessed February9, 2017)
    1. Mera R, McCallister S, Palmer B, et al. . Truvada (TVD) for HIV pre-exposure prophylaxis (PrEP) utilization in the United States (2013–2015). International AIDS Conference (AIDS 2016), Session TUAX01, Abstract TUAX0105LB; Durban, South Africa 2016

Substances